Patients were randomly assigned 1:1 to receive either axitinib 5 mg orally twice daily or matching placebo, both combined with octreotide long-acting release 30 mg, in an international study.

Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...

In addition to the some of the above studies being retrospective, the conflicting data between multiple studies seem to originate from two major issues, the first one being the stage of patients ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...

The speakers emphasize that symptom burden can alter sequencing priorities and prompt greater integration of supportive interventions alongside tumor directed therapy. Regular symptom assessment and ...

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...

Recently published Neuroendocrine Carcinoma Market Insights report includes a comprehensive understanding of current ...

Neuroendocrine Cancer UK (NCUK) says there is an urgent need to speed up the diagnosis of neuroendocrine cancer, which refers to a group of cancers that start in the nerve and gland cells that make ...

This segment addresses treatment planning after progression on second line therapy in progressive small bowel neuroendocrine tumor. Dr Lieu outlines common sequencing strategies following peptide ...